title: [Lymphatic neoplasias in young patients].
authors.affiliation: Klinik I für Innere Medizin, Universitätsklinik Köln, Köln, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Nicola
authors.initials: N
authors.lastname: Gökbuget
authors.forename: Gerald
authors.initials: G
authors.lastname: Wulf
authors.forename: Lorenz
authors.initials: L
authors.lastname: Trümper
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab; D015996:Survival Rate; D055815:Young Adult
chemical_list: D018033:Antibodies, Bispecific; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C510808:blinatumomab